COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?

Siniorakis, Eftychios; Arvanitakis, Spyridon; Sfakianaki, Titika; Katsianis, Antonis; Κωνσταντοπούλου, Γεωργία

doi:10.1093/pm/pnaa300

Cited by 3 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the COVID-19 pandemic stimulated the development of telemedicine applications because all health systems had to face changes. Thus, remote patient–doctor communication was developed with the adjustment of treatment schemes and monitoring of symptoms, a better understanding on the part of patients of risk factors and the importance of cardiovascular prevention, as well as the motivation of patients to self-monitor and engage in self-care [ 18 , 19 , 20 , 21 ].…”

Section: Discussionmentioning

confidence: 99%

“…Although the frequency of face-to-face visits for blood pressure monitoring has decreased, studies have shown that many patients have enrolled in various telemedicine programs for remote blood pressure monitoring and treatment adjustments at home [ 20 ]. Strict government health recommendations to limit the spread of COVID-19 were followed by a reluctance of patients to go to the hospital and have led to a marked reduction in consultations and admissions for cardiovascular disease [ 22 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Challenges in Caring for People with Cardiovascular Disease through and beyond the COVID-19 Pandemic: The Advantages of Universal Access to Home Telemonitoring

et al. 2023

View full text Add to dashboard Cite

(1) Background: Cardiovascular prevention was left in second place during the COVID-19 pandemic and the use of telemedicine turned out to be very useful. We aimed to evaluate the effectiveness of a telemedicine application for remote monitoring and treatment adjustments in terms of improving cardiovascular prevention. (2) Methods: A prospective study of 3439 patients evaluated between the 1st of March 2019 and the 1st of March 2022, in the pre-pandemic period by face-to-face visits and during the pandemic by teleconsultations or hybrid follow-up. We compared four periods: pre-pandemic—Pre-P (1 March 2019–1 March 2020), lockdown—Lock (1 March–1 September 2020), restrictive-pandemic—Restr-P (1 September 2020–1 March 2021), and relaxed–pandemic—Rel-P (1 March 2021–1 March 2022). (3) Results: The average values of total cholesterol (TC), LDL cholesterol, triglycerides, uric acid, and glucose had an increasing trend during Lock and Restr-P, and they decreased close to the baseline level during the Rel-P, with the exception of glucose which remained elevated in Rel-P. The number of patients with newly discovered DM increased significantly in the Rel-P, and 79.5% of them had mild/moderate forms of COVID-19. During Lock and Res-P, the percentage of obese, smoking, or hypertensive patients increased, but probably through the use of telemedicine, we managed to reduce it, although it remained slightly higher than the pre-pandemic level. Physical activity decreased in the first year of the pandemic, but in Rel-P people became more active than before the pandemic. (4) Conclusions: The use of telemedicine for cardiovascular prevention seems to yield favorable results, especially for secondary prevention in the very high-risk group and during the second year.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Challenges in Caring for People with Cardiovascular Disease through and beyond the COVID-19 Pandemic: The Advantages of Universal Access to Home Telemonitoring

et al. 2023

View full text Add to dashboard Cite

show abstract

“… 66 The modulation of the pain pathway anatomical integrity has been reported to be affected by the pharmaceutical treatment for HF. 67 It is reasonable to suggest that missing emergent assistance of COVID‐19 individuals with HF is partly attributed to impaired cardiac pain perception.…”

Section: Discussionmentioning

confidence: 99%

“…However, a noteworthy feature of SARS‐CoV‐2 is the missing diagnosis of patients with co‐morbidity, which could be explained because painful myocardial ischaemia episodes decrease, replaced with silent HF episodes 66 . The modulation of the pain pathway anatomical integrity has been reported to be affected by the pharmaceutical treatment for HF 67 . It is reasonable to suggest that missing emergent assistance of COVID‐19 individuals with HF is partly attributed to impaired cardiac pain perception.…”

Section: Discussionmentioning

confidence: 99%

Uncovering the genetic links of SARS‐CoV‐2 infections on heart failure co‐morbidity by a systems biology approach

et al. 2022

View full text Add to dashboard Cite

Aims The co‐morbidities contribute to the inferior prognosis of COVID‐19 patients. Recent reports suggested that the higher co‐morbidity rate between COVID‐19 and heart failure (HF) leads to increased mortality. However, the common pathogenic mechanism between them remained elusive. Here, we aimed to reveal underlying molecule mechanisms and genetic correlation between COVID‐19 and HF, providing a new perspective on current clinical management for patients with co‐morbidity. Methods The gene expression profiles of HF (GSE26887) and COVID‐19 (GSE147507) were retrieved from the GEO database. After identifying the common differentially expressed genes (|log2FC| > 1 and adjusted P < 0.05), integrated analyses were performed, namely, enrichment analyses, protein–protein interaction network, module construction, critical gene identification, and functional co‐expression analysis. The performance of critical genes was validation combining hierarchical clustering, correlation, and principal component analysis in external datasets (GSE164805 and GSE9128). Potential transcription factors and miRNAs were obtained from the JASPER and RegNetwork repository used to construct co‐regulatory networks. The candidate drug compounds in potential genetic link targets were further identified using the DSigDB database. Results The alteration of 12 genes was identified as a shared transcriptional signature, with the role of immune inflammatory pathway, especially Toll‐like receptor, NF‐kappa B, chemokine, and interleukin‐related pathways that primarily emphasized in response to SARS‐CoV‐2 complicated with HF. Top 10 critical genes (TLR4, TLR2, CXCL8, IL10, STAT3, IL1B, TLR1, TP53, CCL20, and CXCL10) were identified from protein–protein interaction with topological algorithms. The unhealthy microbiota status and gut–heart axis in co‐morbidity were identified as potential disease roads in bridging pathogenic mechanism, and lipopolysaccharide acts as a potential marker for monitoring HF during COVID‐19. For transcriptional and post ‐ transcriptional levels, regulation networks tightly coupling with both disorders were constructed, and significant regulator signatures with high interaction degree, especially FOXC1, STAT3, NF‐κB1, miR‐181, and miR‐520, were detected to regulate common differentially expressed genes. According to genetic links targets, glutathione‐based antioxidant strategy combined with muramyl dipeptide‐based microbe‐derived immunostimulatory therapies was identified as promising anti‐COVID‐19 and anti‐HF therapeutics. Conclusions This study identified shared transcriptomic and corresponding regulatory signatures as emerging therapeutic targets and detected a set of pharmacologic agents targeting genetic links. Our findings provided new insights for underlying pathogenic mechanisms between COVID‐19 and HF.

show abstract

“…In addition, the amplification of messages that those with chronic conditions should stay at home confused and scared patients with cardiovascular conditions, increasing anxiety levels. This led to a delay in the evaluation of symptoms that can hide the aggravation of underlying conditions resulting in delayed acute and preventive care [10].…”

Section: Introductionmentioning

confidence: 99%

Telemedicine for Optimizing Secondary Prevention in Coronary Artery Bypass Grafting Patients during COVID-19 Pandemic

et al. 2023

View full text Add to dashboard Cite

(1) Background: The COVID-19 pandemic has introduced a major disruption to the delivery of secondary prevention measures in patients with established atherosclerotic cardiovascular disease (CVD). It required a rapid and widespread adoption of new medical services, including the use of telemedicine. This study aimed to examine the impact of COVID-19 on secondary prevention in patients with coronary artery bypass grafting (CABG) and to evaluate the effectiveness of the telemedicine application for the implementation of lifestyle change measures, remote monitoring, and treatment regimen adjustment; (2) Methods: This prospective study on 194 CABG patients evaluated three consecutive years between 2019 and 2022 in the pre-pandemic period by face-to-face visits and during the pandemic by teleconsultations or hybrid follow-up. Variables of interest were compared between four periods: pre-pandemic—pre-P (1 March 2019–29 February 2020), lockdown—Lock (1 March–31 August 2020), restrictive-pandemic—Restr-P (1 September 2020–28 February 2021), and relaxed–pandemic—Rel-P (1 March 2021–1 March 2022). (3) Results: The average values of the lipidogram, blood sugar, and uric acid increased during Lock and Restr-P, but, through the use of teleprevention, they returned to the pre-pandemic level or even below this level. The exception was blood sugar, which remained high in Rel-P. The number of newly diagnosed patients with diabetes also increased, with most of them having moderate forms of COVID. During Lock and Res-P, the percentage of obese, smoking, or hypertensive patients increased, but, through the use of teleprevention, we managed to reduce it, although it remained slightly higher than the pre-pandemic level. Physical activity decreased in the first year of the pandemic, but, in Rel-P, CABG patients became more active than before the pandemic (4) Conclusions: The use of telemedicine for cardiovascular secondary prevention allowed us to not only continue seeing CABG patients but, also, to adjust their medication and to expand cardiovascular preventive counseling and testing with favorable results, especially during the second year of the pandemic.

show abstract

COVID-19 Pandemic and Angina Pectoris: What If the Pain Pathway Is Pharmaceutically Modulated?

Cited by 3 publications

References 8 publications

Challenges in Caring for People with Cardiovascular Disease through and beyond the COVID-19 Pandemic: The Advantages of Universal Access to Home Telemonitoring

Challenges in Caring for People with Cardiovascular Disease through and beyond the COVID-19 Pandemic: The Advantages of Universal Access to Home Telemonitoring

Uncovering the genetic links of SARS‐CoV‐2 infections on heart failure co‐morbidity by a systems biology approach

Telemedicine for Optimizing Secondary Prevention in Coronary Artery Bypass Grafting Patients during COVID-19 Pandemic

Contact Info

Product

Resources

About